JP2017519762A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519762A5
JP2017519762A5 JP2016573549A JP2016573549A JP2017519762A5 JP 2017519762 A5 JP2017519762 A5 JP 2017519762A5 JP 2016573549 A JP2016573549 A JP 2016573549A JP 2016573549 A JP2016573549 A JP 2016573549A JP 2017519762 A5 JP2017519762 A5 JP 2017519762A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
polypeptide
human
composition according
vwf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016573549A
Other languages
English (en)
Japanese (ja)
Other versions
JP6688746B2 (ja
JP2017519762A (ja
Filing date
Publication date
Priority claimed from NL2013007A external-priority patent/NL2013007B1/en
Application filed filed Critical
Publication of JP2017519762A publication Critical patent/JP2017519762A/ja
Publication of JP2017519762A5 publication Critical patent/JP2017519762A5/ja
Application granted granted Critical
Publication of JP6688746B2 publication Critical patent/JP6688746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016573549A 2014-06-16 2015-06-16 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用 Active JP6688746B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2013007 2014-06-16
NL2013007A NL2013007B1 (en) 2014-06-16 2014-06-16 Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US201462030817P 2014-07-30 2014-07-30
US62/030,817 2014-07-30
PCT/EP2015/063493 WO2015193326A1 (en) 2014-06-16 2015-06-16 Methods of treating ttp with immunoglobulin single variable domains and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020014229A Division JP7105260B2 (ja) 2014-06-16 2020-01-30 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用

Publications (3)

Publication Number Publication Date
JP2017519762A JP2017519762A (ja) 2017-07-20
JP2017519762A5 true JP2017519762A5 (enExample) 2019-01-17
JP6688746B2 JP6688746B2 (ja) 2020-04-28

Family

ID=51541255

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016573549A Active JP6688746B2 (ja) 2014-06-16 2015-06-16 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用
JP2020014229A Active JP7105260B2 (ja) 2014-06-16 2020-01-30 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用
JP2022110921A Pending JP2022160431A (ja) 2014-06-16 2022-07-11 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020014229A Active JP7105260B2 (ja) 2014-06-16 2020-01-30 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用
JP2022110921A Pending JP2022160431A (ja) 2014-06-16 2022-07-11 免疫グロブリン単一可変ドメインでttpを処置する方法、およびその使用

Country Status (15)

Country Link
US (5) US10858445B2 (enExample)
EP (6) EP3335723B1 (enExample)
JP (3) JP6688746B2 (enExample)
KR (2) KR102568585B1 (enExample)
CN (1) CN106559985A (enExample)
AU (2) AU2015276237B2 (enExample)
CA (1) CA2952103A1 (enExample)
ES (5) ES2831865T3 (enExample)
IL (1) IL249540B (enExample)
NL (1) NL2013007B1 (enExample)
PL (5) PL3335724T3 (enExample)
PT (5) PT3154569T (enExample)
RU (1) RU2704444C2 (enExample)
SG (2) SG10201811109PA (enExample)
WO (1) WO2015193326A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) * 2017-07-13 2019-07-05 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
SG11202006902QA (en) 2018-02-06 2020-08-28 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
IL302984A (en) * 2020-11-18 2023-07-01 Green Cross Corp Adamts13 variant having increased escaping rate or activity against autoantibody
KR20240058167A (ko) 2021-09-17 2024-05-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Sars-cov-2 중화 항체 동정을 위한 합성 인간화 라마 나노바디 라이브러리 및 이의 용도
CN118715246A (zh) * 2021-12-10 2024-09-27 李人浩 结合血管性血友病因子(vwf)a1结构域或自动抑制模块的多肽、变体及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
ES2338321T3 (es) 1992-08-21 2010-05-06 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1157119A1 (en) 1999-02-05 2001-11-28 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1527346B1 (en) 2002-08-07 2011-06-08 Ablynx N.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
RU2524129C2 (ru) 2003-01-10 2014-07-27 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
CA2593328C (en) 2005-01-14 2018-02-06 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets
EP3243839A1 (en) 2005-05-20 2017-11-15 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
ES2663512T3 (es) 2007-05-24 2018-04-13 Ablynx N.V. Secuencias de aminoácidos dirigidas contra RANK-L y polipéptidos que comprenden las mismas para el tratamiento de enfermedades y trastornos óseos
US20110158996A1 (en) 2008-03-21 2011-06-30 Ablynx N.V. Von willebrand factor specific binders and methods of use therefor
MX345226B (es) 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
WO2011067160A1 (en) 2009-12-01 2011-06-09 Ablynx Nv Von willebrand factor specific binding agents and uses thereof
CA2813849C (en) * 2010-11-05 2021-06-15 Novartis Ag Secukinumab for use in the treatment of ankylosing spondylitis
KR20190041032A (ko) 2011-06-10 2019-04-19 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
ES2813432T3 (es) 2011-08-17 2021-03-23 Glaxo Group Ltd Proteínas y péptidos modificados
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
SG11202006902QA (en) 2018-02-06 2020-08-28 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains

Similar Documents

Publication Publication Date Title
JP2017519762A5 (enExample)
JP2017503820A5 (enExample)
JP2018111728A5 (enExample)
JP2018184417A5 (enExample)
JP2015529225A5 (enExample)
JP2018193377A5 (enExample)
JP2015517488A5 (enExample)
JP2015518818A5 (enExample)
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
JP2014515763A5 (enExample)
JP2019519519A5 (enExample)
JP2013533858A5 (enExample)
JP2016529255A5 (enExample)
JP2017031213A5 (enExample)
JP2016513075A5 (enExample)
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
JP2014169326A5 (enExample)
JP2014514346A5 (enExample)
JP2020521797A5 (enExample)
JP2012518624A5 (enExample)
JP2012193216A5 (enExample)
JP2018505882A5 (enExample)
JP2019528285A5 (enExample)
JP2017533972A5 (enExample)
JP2017503014A5 (enExample)